Browsing Tag
NASDAQ
289 posts
Klotho Neurosciences expands beyond the anti-aging gene with Turn Biotechnologies acquisition plan
Klotho Neurosciences moves to buy Turn Bio’s ERA and eTurna assets plus a $300M Korea pharma deal. Explore how this could reshape its longevity pipeline.
How Nuvini’s acquisition of MK Solutions could change Brazil’s ERP market forever
Nuvini Group’s acquisition of MK Solutions adds R$40M revenue and R$20M EBITDA. Find out what this means for SaaS growth and investor sentiment.
Can Beam Global’s new patent finally solve the winter EV charging problem?
Beam Global (NASDAQ: BEEM) secures U.S. patent for cold-weather fast charging tech. Can this innovation revive its struggling stock and reshape EV adoption?
ZYN002 misses pivotal Fragile X trial — What does the setback mean for Harmony’s pipeline and stock outlook?
Harmony’s ZYN002 fails key Fragile X trial, sending HRMY stock lower. Find out why placebo effects mattered and what’s next for its pipeline.
Scilex Holding (SCLX) stock jumps after $200m Semnur Bitcoin deal
Scilex swaps $200M in Semnur stock for Bitcoin as SCLX jumps. See why this bold biotech-crypto move could change investor sentiment and treasury models.
The fibrosis frontier: Can anti-fibrotic drugs finally deliver where weight-loss therapies fall short?
Can anti-fibrotic drugs succeed where weight-loss therapies have stalled? Explore the future of MASH treatment and why fibrosis is the key clinical frontier.
Strive and Semler Scientific plan all-stock Bitcoin bet that unites 10,900 BTC under one roof
Strive (ASST) will buy Semler Scientific (SMLR) in a 210%-premium, all-stock Bitcoin-treasury merger. Find out how this deal could reshape corporate crypto today.
MBX Biosciences stock surges 160% after Canvuparatide Phase 2 success in hypoparathyroidism
MBX Biosciences (NASDAQ: MBX) jumps 160% after Canvuparatide Phase 2 success in hypoparathyroidism; see trial data, stock reaction, and Phase 3 outlook.
SpartanNash buyout: Why its $1.77bn C&S takeover ends a 25-year Nasdaq run and reshapes grocery supply
SpartanNash (NASDAQ: SPTN) goes private in a $1.77B C&S buyout. See what it means for shareholders, grocery rivals, and the sector’s future.
Why Envoy Medical is raising $2.5m at-the-market and what it means for COCH investors
Envoy Medical raises $2.5M via Nasdaq-compliant at-market offering. Learn how the move impacts COCH stock, liquidity, and investor sentiment.